Morepen Laboratories (NSE:MOREPENLAB) filed an exchange announcement on 4 August 2026 disclosing that its board approved unaudited Q1 FY27 financial results, set a dividend record date of 19 September 2026, extended the timeline for hiving off its medical devices business, and proposed reappointment of Chairman and Managing Director Mr. Sushil Suri.
Key Highlights
- Consolidated revenue from operations for Q1 FY27 (quarter ended 30 June 2026) rose to Rs 57,012.81 lakhs, compared with Rs 42,523.88 lakhs in Q1 FY26, representing year-on-year growth.
- Consolidated net profit after minority interest for Q1 FY27 stood at Rs 5,639.94 lakhs, compared with Rs 1,074.83 lakhs in Q1 FY26.
- The board set 19 September 2026 as the record date for determining members eligible for the final dividend for FY26, subject to shareholder approval at the 41st AGM.
- The 41st AGM is scheduled for 26 September 2026, to be held via video conferencing, where shareholders will vote on the dividend, CMD reappointment, and the medical devices business hive-off timeline extension.
About the Company
Morepen Laboratories (NSE:MOREPENLAB) is a Baddi, Himachal Pradesh-headquartered pharmaceutical and healthcare company with operations in active pharmaceutical ingredients (APIs), formulations, and consumer healthcare products, including Dr. Morepen-branded diagnostics and wellness devices. The company operates manufacturing facilities in Baddi and holds subsidiaries in India, USA, and UAE, serving domestic and international markets across the pharma and healthcare sector.
Announcement in Detail
The board meeting commenced at 11:30 a.m. and concluded at 1:20 p.m. on 4 August 2026. The board approved unaudited standalone and consolidated financial results for Q1 FY27, based on the Audit Committee's recommendation under Regulation 33 of the SEBI Listing Regulations. Consolidated total income for the quarter reached Rs 57,531.15 lakhs, up from Rs 42,964.73 lakhs in Q1 FY26, while consolidated profit before tax was Rs 7,452.74 lakhs against Rs 1,551.64 lakhs in the year-ago quarter.
Additionally, the board approved extending the timeline for hiving off the Medical Devices Business into Morepen Medipath Limited (formerly Morepen Medtech Limited), a wholly owned subsidiary, on a slump sale basis as a going concern, subject to shareholder approval at the 41st AGM. Mr. Sushil Suri (DIN: 00012028) has been proposed for reappointment as Chairman and Managing Director for a further three-year term from 20 October 2026 to 19 October 2029, subject to member approval at the same AGM.
Impact on Investors
Investors will note that the consolidated net profit after minority interest of Rs 5,639.94 lakhs for Q1 FY27 represents a marked improvement compared with Rs 1,074.83 lakhs in Q1 FY26, as disclosed in the filing. The record date of 19 September 2026 for the final FY26 dividend is relevant for shareholders tracking their eligibility, though the dividend amount is yet to be formally confirmed until approved by members at the 41st AGM on 26 September 2026.
The disclosed terms indicate that the hive-off of the Medical Devices Business into Morepen Medipath Limited remains contingent on both shareholder approval at the AGM and completion of the extended timeline. Shareholders will observe that this is a material related party transaction and board approval alone does not constitute final clearance; member consent at the forthcoming AGM is required before the transaction can proceed.
Sector / Market Context
India's pharmaceutical sector has been a consistent contributor to export earnings, with the industry's exports exceeding USD 27 billion in FY26 according to Pharmaceuticals Export Promotion Council of India (Pharmexcil) data. The API segment, in which Morepen Laboratories maintains a significant presence, has received policy support under India's Production Linked Incentive scheme for bulk drugs, aimed at reducing import dependence and strengthening domestic manufacturing capacity. This structural backdrop frames the company's continued capacity investments and subsidiary structuring decisions.